TABLE 2.
Molecular recurrence risk and hazard ratios from univariate Cox models according to selected variables.
| N. patients | N. molecular recurrence (%) | HRs | 95% CI | p | |
|---|---|---|---|---|---|
| Gender | |||||
| M | 110 | 30 (27.3) | 1.00 | Reference | |
| F | 138 | 46 (33.3) | 1.28 | 0.81–2.02 | 0.30 |
| Sokal risk | |||||
| Low | 122 | 39 (32.0) | 1.00 | Reference | |
| Intermediate | 78 | 20 (25.6) | 0.81 | 0.47–1.38 | 0.43 |
| High | 33 | 15 (45.4) | 1.55 | 0.86–2.82 | 0.15 |
| ELTS risk | |||||
| Low | 181 | 58 (32.0) | 1.00 | Reference | |
| Intermediate | 37 | 13 (35.1) | 1.11 | 0.61–2.03 | 0.73 |
| High | 13 | 3 (23.1) | 0.73 | 0.23–2.34 | 0.60 |
| Transcript type | |||||
| e14a2 | 155 | 44 (28.4) | 1.00 | Reference | |
| e13a2 | 56 | 22 (39.3) | 1.65 | 0.99–2.75 | 0.06 |
| e14a2/e13a2 | 19 | 7 (36.8) | 1.36 | 0.61–3.03 | 0.44 |
| Previous IFN | |||||
| NO | 209 | 67 (32.1) | 1.00 | Reference | |
| YES | 39 | 9 (23.1) | 0.62 | 0.31–1.24 | 0.18 |
| First-line TKI | |||||
| Imatinib | 177 | 54 (30.5) | 1.00 | Reference | |
| Dasatinib | 20 | 10 (50.0) | 1.73 | 0.88–3.41 | 0.11 |
| Nilotinib | 51 | 12 (23.5) | 0.81 | 0.43–1.51 | 0.50 |
| Reason for dose reduction | |||||
| MR achievement | 100 | 32 (32.0) | 1.00 | Reference | |
| AEs | 148 | 44 (29.7) | 0.87 | 0.55–1.37 | 0.55 |
| Duration of TKIs (years) | |||||
| <10 | 142 | 45 (31.7) | 1.00 | Reference | |
| ≥10 | 106 | 31 (29.2) | 0.89 | 0.56–1.40 | 0.60 |
| Last TKI at discontinuation | |||||
| Imatinib | 99 | 27 (27.3) | 0.75 | 0.47–1.21 | 0.24 |
| 2/3G-TKIs | 149 | 49 (32.9) | 1.00 | Reference | |
| Line of therapy at discontinuation | |||||
| First-line | 152 | 45 (29.6) | 0.82 | 0.52–1.30 | 0.41 |
| Second- or later lines | 96 | 31 (32.3) | 1.00 | Reference | |
| Resistance to previous TKIs | |||||
| YES | 47 | 24 (51.1) | 1.00 | Reference | |
| NO | 201 | 52 (25.9) | 2.45 | 1.51–3.98 | 0.000 |
| DMR degree at TFR | |||||
| MR4.0 | 55 | 18 (32.7) | 1.00 | Reference | |
| ≥MR4.5 | 190 | 56 (29.5) | 0.86 | 0.50–1.46 | 0.57 |
| Duration of DMR (years) | |||||
| <4.2 | 84 | 32 (38.1) | 1.00 | Reference | |
| 4.2–6.7 | 81 | 24 (29.6) | 0.71 | 0.42–1.21 | 0.21 |
| ≥6.8 | 83 | 20 (24.1) | 0.57 | 0.33–0.99 | 0.05 |
Abbreviations: M, male; F, female; MR, molecular response; AEs, adverse events; DMR, deep molecular response; HR, hazard ratio; CI, confidence interval. Bold values are statistically significant.